Dr. Reddy's Laboratories Ltd (RDY)
NYSE: RDYHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
RDY stock chart
Technical analysisKey statistics
All statistics- Market cap
- $12.41B
- P/E (TTM)
- 41.36
- Forward P/E
- 22.47
- EPS (TTM)
- $0.36
- Dividend yield
- 53.73% ($8.00)
- Ex-dividend date
- Jul 24, 2026
- 52-week range
- 11.36 – 15.67
- Day range
- 14.86 – 15.10
- Volume / Avg
- 1.74M / 2.85M
- Beta
- —
- Shares outstanding
- 833.66M
52-week range
RDY stock today
On Nov 20, RDY ended the session at $14.89, adding $0.06 (0.40%), versus the S&P 500's 3.70% decline. Shares are 5.0% below their 52-week high of $15.67, set on Jun 26, 2026 and 31.1% above the 52-week low of $11.36, near the top of the past year's range. RDY is up 6.1% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 7.0%.
Dr. Reddy's Laboratories trades at 41.4x its trailing twelve-month earnings per share of $0.36. Its forward P/E of 22.5x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Dr. Reddy's Laboratories pays an annual dividend of $8.00 per share, a 53.73% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About Dr. Reddy's Laboratories
Company profileDr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Erez Israeli M.B.A.
- Headquarters
- Hyderabad
- Employees
- 27,527
- Website
- drreddys.com
Financial highlights
Full financialsIn fiscal 2025, Dr. Reddy's Laboratories generated $3.81 billion in revenue, up 13.8% from fiscal 2024, its 7th consecutive year of revenue growth. Net income was $663.0 million (-0.7% year over year), for a net margin of 17.4% versus a median of 11.2% in the prior 5 years. Gross margin was 58.5% (down from 58.6%) and operating margin 22.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $3.81B | $3.35B | $2.99B | $2.83B | $2.59B |
| Growth | +13.76% | +11.97% | +5.87% | +8.94% | +12.00% |
| Net income | $663.00M | $668.00M | $548.00M | $311.00M | $236.00M |
| EPS (diluted) | $0.79 | $4.01 | $3.30 | $1.87 | $1.52 |
Analyst forecast
ForecastConsensus (5 analysts)
buy
Avg. price target
$14.92+0.20%
- Strong buy 1
- Buy 2
- Hold 1
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 23, 2026
- EPS actual vs est.
- $0.19 vs $0.16
- Surprise
- +18.75%
Dividends
Dividend history- Annual dividend
- $8.00
- Dividend yield
- 53.73%
- Last payment
- $0.083
- Ex-dividend date
- Jul 24, 2026
RDY news
All RDY news- Dr. Reddy's Laboratories Limited Announces USFDA Closes Inspection at FTO-3 FacilityNasdaqRDY, LEN.B
- Weekly Buzz: RDY, LUPIN, SUNPHARMA Score FDA Wins; AGIO, RARE Slash Jobs; CVS Plots SplitNasdaqABT, AGIO, BEAT, BIOA
- Dr. Reddy's Laboratories Limited Receives Marketing Authorization for Generic Semaglutide Injection in BrazilNasdaq
- Dr.Reddy's Wins Brazil Approval For Generic Ozempic AlternativeNasdaqRDY, BRK.A
- Dr. Reddy's Laboratories Limited Allots 5,91,270 Equity Shares Under Employees ADR Stock Options Scheme, 2007Nasdaq
- Reddy's Gets Tentative FDA Nod For Twice-Yearly HIV Prevention Shot At $40 A YearNasdaq
- Dr. Reddy's Laboratories Limited Announces USFDA Classifies FTO-SEZ Process Unit-02 Inspection as Voluntary Action IndicatedNasdaq
- RDY Q2 Earnings & Revenues Miss Estimates as Lenalidomide Sales FallNasdaqRDY, HALO, TGTX, HRMY
Dr. Reddy's Laboratories peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ELANElanco Animal Health Incorporated | 25.74 | -2.09% | $12.87B | vs RDY |
| BMRNBioMarin Pharmaceutical Inc. | 60.41 | -1.64% | $11.70B | vs RDY |
| JAZZJazz Pharmaceuticals plc | 230.26 | -2.62% | $14.78B | vs RDY |
| BBIOBridgeBio Pharma Inc. | 76.03 | -2.75% | $14.81B | vs RDY |
| TGTXTG Therapeutics Inc. | 63.34 | -2.37% | $9.57B | vs RDY |
| SYRESpyre Therapeutics Inc. | 93.47 | -4.26% | $8.88B | vs RDY |
| MDGLMadrigal Pharmaceuticals Inc. | 379.10 | -4.45% | $8.81B | vs RDY |
| PRAXPraxis Precision Medicines Inc. | 300.43 | -3.37% | $8.40B | vs RDY |
Indexes, lists and sector
Dr. Reddy's Laboratories stock FAQ
What is Dr. Reddy's Laboratories's stock price today?
RDY last traded at $14.89 as of Nov 20, 4:00 PM EST, up 0.40% on the day. Prices are delayed at least 15 minutes.
Does Dr. Reddy's Laboratories pay a dividend?
Yes. Dr. Reddy's Laboratories pays $8.00 per share annually, a 53.73% yield. The most recent dividend of $0.083 had an ex-dividend date of Jul 24, 2026.
What is RDY's P/E ratio?
RDY trades at a trailing P/E ratio of 41.36 and a forward P/E of 22.47.
Who is Dr. Reddy's Laboratories's CEO?
Mr. Erez Israeli M.B.A. is the chief executive officer of Dr. Reddy's Laboratories Ltd, which has about 27,527 employees.
Has RDY ever split its stock?
Yes. The most recent RDY stock split was a 5-for-1 split on Nov 5, 2024, one of 2 splits on record.
What is the RDY 52-week high?
The 52-week high for RDY is $15.67 and the 52-week low is $11.36. The stock is currently 5.0% below its high.